Technical Analysis for NTRA - Natera, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
A | 167.88 | 3.57% | 5.78 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing High | Bullish | 0.00% | |
New 52 Week High | Strength | 0.00% | |
Stochastic Reached Overbought | Strength | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
New 52 Week Closing High | Bullish | 3.57% |
Alert | Time |
---|---|
Up 1 ATR | about 18 hours ago |
New 52 Week High | about 19 hours ago |
Up 3% | about 19 hours ago |
60 Minute Opening Range Breakout | about 20 hours ago |
1.5x Volume Pace | about 20 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 11/12/2024
Natera, Inc. Description
Natera, Inc., a genetic testing company, develops and commercializes non-invasive methods for analyzing deoxyribonucleic acid (DNA) in the United States and Europe. The company primarily offers Panorama, a non-invasive prenatal test for fetal chromosomal abnormalities; Horizon test; and pre-implantation genetic screening and pre-implantation genetic diagnosis tests under the Spectrum brand to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization. It also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal DNA in a pregnant mother's blood and a blood sample from the alleged father; and high throughput carrier screening to determine the risk of passing severe genetic diseases on to offspring. Natera sells its tests directly and partner with other clinical laboratories to distribute its tests. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Classification
Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Clinical Medicine Acid IBD 50 Medical Genetics Medical Test Lab Testing In Vitro Applied Genetics Genetic Diseases Genetic Testing DNA DNA Paternity Testing Prenatal Testing Severe Genetic Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 169.71 |
52 Week Low | 53.6183 |
Average Volume | 1,240,346 |
200-Day Moving Average | 107.81 |
50-Day Moving Average | 129.84 |
20-Day Moving Average | 135.20 |
10-Day Moving Average | 147.51 |
Average True Range | 7.44 |
RSI (14) | 73.47 |
ADX | 37.84 |
+DI | 50.16 |
-DI | 10.67 |
Chandelier Exit (Long, 3 ATRs) | 147.40 |
Chandelier Exit (Short, 3 ATRs) | 139.58 |
Upper Bollinger Bands | 166.15 |
Lower Bollinger Band | 104.26 |
Percent B (%b) | 1.03 |
BandWidth | 45.77 |
MACD Line | 9.42 |
MACD Signal Line | 5.65 |
MACD Histogram | 3.7755 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 182.18 | ||||
Resistance 3 (R3) | 181.20 | 175.45 | 179.79 | ||
Resistance 2 (R2) | 175.45 | 171.81 | 175.94 | 179.00 | |
Resistance 1 (R1) | 171.67 | 169.56 | 173.56 | 172.65 | 178.20 |
Pivot Point | 165.92 | 165.92 | 166.87 | 166.41 | 165.92 |
Support 1 (S1) | 162.14 | 162.28 | 164.03 | 163.12 | 157.56 |
Support 2 (S2) | 156.39 | 160.03 | 156.88 | 156.76 | |
Support 3 (S3) | 152.61 | 156.39 | 155.97 | ||
Support 4 (S4) | 153.59 |